2 results
Approved WMOCompleted
Primary Objective: The primary objective for this study is to compare the efficacy of ABP 215 with bevacizumab.Secondary Objective(s): The secondary objectives are to assess the safety and immunogenicity of ABP 215 compared with bevacizumab.
Approved WMORecruiting
The study is divided in two phases.The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of ex vivo expanded UCB-NK cells, both with and without sc IL-2 following immunosuppressive conditioning therapy…